In yesterday’s Wall Street session, Heron Therapeutics Inc (NASDAQ:HRTX) shares traded at $1.95, up 4.84% from the previous session.
HRTX stock price is now -36.76% away from the 50-day moving average and -20.88% away from the 200-day moving average. The market capitalization of the company currently stands at $295.76M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $7, Rodman & Renshaw recently initiated with Buy rating for Heron Therapeutics Inc (NASDAQ: HRTX). On April 23, 2024, CapitalOne recently initiated its ‘Overweight’ rating on the stock quoting a target price of $6, while ‘Needham’ rates the stock as ‘Buy’
In other news, Forbes William P, EVP, Chief Development Officer bought 25,000 shares of the company’s stock on Nov 17 ’23. The stock was bought for $27,250 at an average price of $1.09. Upon completion of the transaction, the EVP, Chief Development Officer now directly owns 79,000 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16 ’23, EVP, Chief Development Officer Forbes William P bought 50,000 shares of the business’s stock. A total of $46,995 was incurred on buying the stock at an average price of $0.94. This leaves the insider owning 54,000 shares of the company worth $0.11 million. A total of 7.42% of the company’s stock is owned by insiders.
During the past 12 months, Heron Therapeutics Inc has had a low of $0.50 and a high of $3.93. The fifty day moving average price for HRTX is $3.084 and a two-hundred day moving average price translates $2.46475 for the stock.
The latest earnings results from Heron Therapeutics Inc (NASDAQ: HRTX) was released for 2024-06-30. The company reported revenue of $36.02 million for the quarter, compared to $31.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.42 percent. For the current quarter, analysts expect HRTX to generate $36.62M in revenue.
